GlassScriptPhysician profile
Lance B Friedland
NPI 1700872298
$5,570.33
in general payments reported to CMS, 2019-2025
29 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $666 · 2021: $1,029 · 2022: $525 · 2023: $987 · 2024: $659 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,395.69 | 2019-2024 | Xarelto |
| Amgen INC. | $578.80 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $554.22 | 2019-2025 | |
| Boston Scientific Corporation | $480.53 | 2019-2025 | Bodyguardian, Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $455.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $358.90 | 2021-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $255.27 | 2022-2025 | Verquvo, Capvaxive |
| Cvrx, INC. | $237.18 | 2024-2025 | Barostim Neo System |
| Abbott Laboratories | $172.57 | 2024 | |
| Amarin Pharma, INC. | $156.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.37 | 2022-2025 | Jardiance |
| Heartflow, INC. | $113.10 | 2023-2025 | Ffrct |
| Edwards Lifesciences Corporation | $111.98 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $75.98 | 2019-2025 | Farxiga |
| Abiomed | $73.72 | 2024-2025 | Impella |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $62.06 | 2021-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.83 | 2019-2023 | Lifevest |
| Esperion Therapeutics, INC. | $55.13 | 2021-2023 | Nexletol |
| Glaxosmithkline, LLC. | $43.43 | 2025 | Arexvy, Shingrix |
| Innovation Technologies INC | $43.06 | 2025 | Irrisept |
| Sanofi-Aventis U.S. LLC | $33.71 | 2023-2024 | |
| Portola Pharmaceuticals, LLC | $19.84 | 2020 | |
| Chiesi USA, INC. | $16.74 | 2019 | |
| Akcea Therapeutics, INC. | $16.47 | 2021 | |
| Medtronic Vascular, INC. | $13.57 | 2020 | |
| Medtronic, INC. | $13.55 | 2021 | |
| Lundbeck LLC | $13.13 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Friedland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.